Evidence-based therapy for recurrent cervical cancer

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2687-2690

  Monk, Bradley J ^a   Tewari, Krishnansu S ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADULT; BACKACHE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CASE REPORT; CHEMORADIOTHERAPY; EVIDENCE BASED PRACTICE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE PULMONARY NODULES; PELVIS TUMOR; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; CARCINOMA, SQUAMOUS CELL; EVIDENCE BASED MEDICINE; NEOPLASM RECURRENCE, LOCAL; RISK FACTOR; UTERINE CERVICAL NEOPLASMS;

ADULT; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84906815244     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.8733     Document Type: Review

References (14)

1. US Food and Drug Administration: Manufacturer's (Merck Sharp & Dohme's) highlights of prescribing information for Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) suspension for intramuscular injection. http://www.fda.gov/downloads/ biologicsbloodvaccines/vaccines/approvedproducts/ucm111263.pdf
2. Moyer VA, U.S. Preventive Services Task Force: Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 156:880-891, 2012
3. Monk BJ, Tewari KS, Koh WJ: Multimodality therapy for locally advanced cervical carcinoma: State of the art and future directions. J Clin Oncol 25:2952-2965, 2007
4. Monk BJ, Tian C, Rose PG, et al: Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials. Gynecol Oncol 105:427-433, 2007
5. Lin JF, Berger JL, Krivak TC, et al: Impact of facility volume on therapy and survival for locally advanced cervical cancer. Gynecol Oncol 132:416-422, 2014
6. Moore DH, Tian C, Monk BJ, et al: Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 116:44-49, 2010
7. Tewari KS, Sill MW, Monk BJ, et al: Prospective validation of pooled prognostic factors in advanced cervical cancer: A Study of the Gynecologic Oncology Group. Society of Gynecologic Oncology 45th Annual Meeting on Women's Cancer, Tampa, FL, March 22-25, 2014 (abstr 143-144)
8. Monk BJ, Sill MW, McMeekin DS, et al: Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 27:4649-4655, 2009
9. Tewari KS, Sill MW, Long HJ 3rd, et al: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734-743, 2014
10. Kitagawa R, Katsumata N, Shibata T, et al: A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505). J Clin Oncol 30:328s, 2012 (suppl; abstr 5006)
11. Moore DH, Blessing JA, McQuellon RP, et al: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 22:3113-3119, 2004
12. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al: Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol 23:4626-4633, 2005
13. Monk BJ, Sill MW, Burger RA, et al: Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 27:1069-1074, 2009
14. Miller DS, Blessing JA, Ramondetta LM, et al: Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: A limited access phase II trial of the Gynecologic Oncology Group. J Clin Oncol (in press)